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Excessive immune activation and inﬂammatory mediators may play a critical role in the pathogenesis of chronic heart failure.
Methotrexate is a commonly used anti-inﬂammatory and immunosuppressive drug. In this study, we used a rat model of cardiac
myosin-induced experimental autoimmune myocarditis to investigate the eﬀects of low-dose methotrexate (0.1mg/kg/d for
30d) on the plasma level of cytokines and cardiac remodeling and function. Our study showed that levels of tumor necrosis
factor-(TNF-)alpha and interleukin-6 (IL-6) are signiﬁcantly increased in postmyocarditis rats, compared with the control rats.
Methotrexate treatment reduced the plasma levels of TNF-alpha and IL-6 and increased IL-10 level, compared to saline treatment.
In addition, postmyocarditis rats showed signiﬁcant cardiac ﬁbrosis characterized by increased myocardial collagen volume
fraction, perivascular collagen area, and the ratio of collagen type I to type III, compared with the control rats. However, MTX
treatmentnotonlymarkedlyattenuatedcardiacﬁbrosis,diminishedtheleftventricularend-diastolicdimension,butalsoincreased
the left ventricular ejection fraction and fractional shortening. Collectively, these results suggest that low-dose methotrexate has
ability to regulate inﬂammatory responses and improves cardiac function and hence contributes to prevent the development of
postmyocarditis dilated cardiomyopathy.
Copyright © 2009 Zhengang Zhang et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Congestive heart failure (CHF) is the leading cause of car-
diovascular morbidity and mortality. While state-of-the-art
therapeutics, including β-blockers, angiotensin-converting
enzyme inhibitors, and angiotensin-receptor blockers, are
available to manage CHF, the prognosis for patients with this
condition remains poor [1]. Patients with acute myocarditis
generallyexperiencefullrecoveryfollowingtreatmentforthe
myocardial inﬂammation. However, some patients progress
to persistent myocardial inﬂammation and subsequently
develop dilated cardiomyopathy (DCM) along with CHF.
Increasing evidence suggests that immune activation and
inﬂammatory mediators may play a role in the development
and progression of CHF [2, 3]. For example, elevated plasma
concentrations of the proinﬂammatory cytokines tumor
necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-
6) have been frequently observed in patients with CHF
[4]. Plasma levels of these cytokines closely correlate with
the severity of CHF; they also provide valuable predictive
information regarding the patient’s prognosis and the rate
of new-onset heart failure [5]. Furthermore, elevated TNF-
alphainmice,increasedbycardiacrestrictedover-expression
or chronic infusion, facilitates the occurrence of typical
phenotypes of CHF [6, 7]. Several studies have shown that
patients with some diseases characterized by inﬂamma-
tory mediator activation (e.g., rheumatoid arthritis, septic
shock) are more prone to developing CHF [8]. It is well2 Mediators of Inﬂammation
known that IL-10 is a potent anti-inﬂammatory cytokine.
Intraperitoneal administration of recombinant human IL-
10 into mice with experimental viral myocarditis appeared
to improve survival, attenuate myocardial inﬂammation
and decrease the myocardial mRNA expression of TNF-
alpha, IL-2, and inducible NO synthase [9]. In peripheral
blood mononuclear cells from CHF patients, IL-10 reduced
lipopolysaccharide-stimulated TNF-alpha production [10].
Moreover, previous study demonstrated level of IL-10 was
reduced in patients with CHF [11]. Therefore, it is likely that
restoring the balance between pro- and anti-inﬂammatory
cytokines would be a useful treatment of CHF, especially
for subjects with proven increased inﬂammatory activation.
Traditional cardiovascular drugs appear to have little eﬀect
ontheabnormallyactivatedinﬂammatorymediatornetwork
associated with CHF [12]. In contrast, several nonspe-
ciﬁcanti-inﬂammatorytreatmentsandimmune-modulating
therapeutics have demonstrated favorable eﬀects against
CHF [2].
Left ventricular remodeling, as an independent deter-
minant of prognosis and an important therapeutic target
in heart failure, is clinically deﬁned as changes in volume,
shape,and/orfunctionofthechamberinresponse tovarious
chronic stresses such as ischemia, pressure/volume overload,
and inﬂammation. High-dose (20–250mg/kg) methotrexate
(MTX) treatment has been indicated for the treatment of
neoplastic diseases, such as acute lymphoblastic leukemia
and solid cancers, due to its inhibitory eﬀect on de novo
purine and pyrimidine synthesis through dihydrofolate
reductase. In contrast, low-dose MTX treatment has been
used as a novel immune modulation therapy [13]. Indeed,
MTX has been extensively applied to the management
of autoimmune and chronic inﬂammatory diseases, such
as rheumatoid arthritis. MTX is eﬀective against these
conditions through its nonspeciﬁc modulation of inﬂam-
matory mediators [14]. In the present study, we used a rat
model of experimental autoimmune myocarditis (EAM) by
immunization with cardiac myosin to investigate the eﬀects
oflow-doseMTXonproandanticytokineproductionaswell
as ventricular remodeling and function.
2.MaterialsandMethods
2.1.Reagents. PorcinecardiacmyosinandFreund’scomplete
adjuvant were purchased from Sigma (St Louis, MO). MTX
(injectable) was obtained from Hualian Pharmaceutical
Technology (Shanghai, China). Polyclonal antibodies against
collagen I and III and SABC (rabbit IgG)-POD kit were
from Wuhanboster Biological Technology (Wuhan, China).
Masson’s trichrome stain kit was from Fuzhou Dongqi
Biological Technology (Fuzhou, China). The ELISA kits used
to measure TNF-alpha, IL-6 and IL-10 were from R & D
Systems China Co. Ltd (Shanghai, China).
2.2. Experimental Autoimmune Myocarditis (EAM) Model.
Thirty male, seven-week-old, speciﬁc-pathogen-free Lewis
rats, weighing 150–200g, were purchased from the Beijing
Vital River Laboratory Animal Technology. A classical model
of EAM was induced in 20 of the rats by immunization
with porcine cardiac myosin, as previously described with
minor modiﬁcations [15]. Brieﬂy, porcine cardiac myosin
was dissolved in 0.2M phosphate-buﬀered saline (PBS) at
a concentration of 10mg/mL and then emulsiﬁed with an
equal volume of Freund’s complete adjuvant supplemented
withMycobacteriumtuberculosisH37Raataconcentrationof
10mg/mL. To induce EAM, Lewis rats were subcutaneously
injected twice (once on day 0 and once at day 7) in each
rear foot pad with 0.1mL of the emulsiﬁed solution. The
remaining ten rats were injected with an equal volume of
saline in the same manner (control group). All experimental
and control animals received humane care and were main-
tained in the institute’s animal facilities under a controlled
temperature (22–26
◦C) and humidity (50%–60%) and given
free access to water and standard rat chow. All experimental
procedures and protocols were approved by the Special
Committee on Animal Welfare of Yangzhou University. The
guidelines set by this committee conform to the Guide for
the Care and Use of Laboratory Animals published by the US
National Institutes of Health (NIH Publication Number 85-
23, revised 1996).
2.3.TreatmentProtocol. Thirtydaysafterimmunizationwith
cardiac myosin, the rats (EAM30 group, n = 20) were
randomly assigned to receive an intraperitoneal injection
of either saline (EAM60 group, n = 10) or 0.1mg/kg
MTX (EAM-MTX group, n = 10), each day for 30 days.
Additionally, the control group was injected with saline (n =
10) daily for 30 days. The intraperitoneal LD50 of MTX for
rats is 6–25mg/kg [16]. In the present study, we deﬁned
the low-dose MTX protocol as daily injections of 0.1mg/kg,
based upon data from a preliminary study.
2.4. Echocardiographic Studies. Echocardiographic studies
were performed on days 30 and 60 after immunization
with cardiac myosin. Rats were weighed and anesthetized
by intraperitoneal injection with a mixture of ketamine
(25mg/kg) and diazepam (5mg/kg). The left ventricular
remodeling and function were assessed by transthoracic
echocardiography using an 8–11MHz phased-array trans-
ducer (SONOS 7500, Philips Medical Systems). A 2D
targeted M-mode echocardiogram was obtained at the level
of the chordae tendineae. The following parameters were
measured from M- and B-mode tracing: left ventricular end-
diastolicdimension(LVEDD,mm),leftventricleend-systolic
dimension (LVESD, mm), interventricular septum thickness
(IVST, mm), left ventricle posterior wall thickness (LVPWT,
mm), left ventricle ejection fraction (LVEF, %), stroke
volume (SV, μL), and fractional shortening (FS, %). All
parameters were measured using the leading-edge method
of the American Society of Echocardiography from three
consecutive cardiac cycles, and the average was used for data
analysis. Measurements were performed blindly by two inde-
pendent investigators. Relative wall thickness (RWT) and left
ventricularmassindex(LVMI,mg/g)werecalculatedaccord-
ing to following formula [17]: RWT = LVEDD/(IVST +
LVPWT), LVM = 0.8[1.04(LVEDD +IVSTd+LVPWTd)
3 −
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2.5. ELISA Detection of Plasma Cytokine Levels. Under anes-
thesia with a mixture of ketamine and diazepam, blood was
drawn from unilatelal eyeball excision on day 30 and from
the cardiac ventricular on day 60. All samples were imme-
diately transferred into prechilled tubes containing 75μLo f
10% EDTA-Na2. Blood samples were instantly centrifuged at
1000×gf o r2 0m i n u t e sa t4 ◦C. Plasma was stored at −70
◦C
forlateranalysis.ConcentrationsofTNF-alpha,IL-6,andIL-
10 were measured in plasma, using commercially available
ELISA kits according to the manufacturer’s instructions.
Eachsamplewasassayedinduplicateandthemeanvaluewas
calculated. The intraassay coeﬃcients of variance were 3.1%,
7.4%, and 3.4%, respectively. The interassay coeﬃcients of
variance were 9.7%, 8.4%, and 8.7%, respectively.
2.6. Histopathologic Assessment. On day 60, all rats were
bled from cardiac ventricle and then sacriﬁced under anes-
thesia. Hearts were removed, rinsed in ice-cold PBS, and
transected at the base of the papillary muscles. Transverse
sections were ﬁxed with 10% (v/v) phosphate buﬀered
formalin for 12 hours and then embedded in paraﬃn.
Paraﬃn-embedded tissues were cut into 2μm thick sections.
Sections were stained with hematoxylin-eosin (HE) and
Masson’s trichrome, according to conventional histological
examination techniques. Randomly selected ﬁelds (12 per
section at a 200 × magniﬁcation) were digitized and subject
to color threshold analysis. In this analysis, green tissue
represents ﬁbrosis while red tissue represents myocardium.
Collagen volume fraction (CVF) and perivascular collagen
area (PVCA) were measured, based on the green (positive)
stainedarea,whichscatteredbetweenthesurvivingmyocytes
and around the blood vessels, respectively.
Several consecutive sections were used for immuno-
histochemical staining. Brieﬂy, deparaﬃnized and hydrated
sectionswerequenchedwith3%hydrogenperoxide,digested
with compound digestive juice followed by blocking with
5% bovine serum albumin. Tissues were then incubated
with the primary antibody, rabbit antirat collagen types I
or type III diluted at 1/150, overnight at 4◦C. The SABC
kit was used for the subsequent steps according to the
manufacturer’s instructions. Chromogenic development was
accomplished using diaminobenzidine-hydrogen peroxide.
Slides were then slightly counterstained with hematoxylin
and dehydrated, and coverslips were applied. Areas of
collagen I and III staining were determined using electronic
imaging of the positively stained area, at a 200× magniﬁca-
tion. The results are expressed as an area ratio of collagen I
to collagen III. The positively stained border zone of vessels
was excluded from all calculations. All measurements were
quantiﬁed by using NIH Image, version 1.30 for Windows.
2.7. Statistical Analysis. Data were expressed as mean ± SD.
SPSS 12.0 was used for statistical analysis of the data. All
data were subjected to one-way ANOVA or t-tests. Statistical
signiﬁcance was inferred at P<. 05 or P<. 01.
3. Results
3.1. General Characteristics and Mortality. All rats in the
EAM30 group had developed foot ulcers and ankle arthro-
cele; which were sustained until the end of the study. Prior
to being assigned to MTX or saline treatment, the rats
which had induced EAM exhibited similar heart rate, blood
pressure, and body weight (data not shown). The body
weight gain in the control group was higher than in the
EAM30group(368.5±20.5gversus307.2±15.8g).However ,
the mean body weight of the EAM60 group rats was
signiﬁcantly higher than that of the control group (422.5 ±
17.7g versus 383.3 ± 18.9g). Compared with the EAM-60
group, there was a signiﬁcant decrease of weight gain in
the EAM-MTX group (365.7 ± 12.7g versus 422.5 ± 17.7g).
Also, the foot ulcers and ankle arthrocele were markedly
attenuatedintheEAM-MTXgroup.Whilethisstudywasnot
designed to statistically evaluate diﬀerences between groups
in rat survival, it should be noted that no diﬀerences in
mortality were observed between treatments.
3.2. Plasma Cytokine Levels. To determine if MTX treatment
alters plasma levels of TNF-alpha, IL-6, and IL-10, plasma
was isolated and then analyzed by ELISA. As shown in
Figure 1, the EAM30 group showed signiﬁcantly elevated
plasma levels of TNF-alpha (14.7-fold) and IL-6 (7.1-fold),
compared with the control group (Figures 1(a) and 1(b)).
However, no signiﬁcant diﬀerence in plasma IL-10 levels
was observed between the two groups (Figure 1(c)). On day
60, the plasma levels of both TNF-alpha and IL-6 were
signiﬁcantly decreased in the EAM60 group, whereas IL-
10 was not changed compared with the EAM30 group.
Compared with the EAM60 group, there were signiﬁcant
decreases of the levels of TNF-alpha (−54.8%) and IL-6
(−48.0%) and an increase of IL-10 (68.3%) in the EAM-
MTXgroup.AllcytokinelevelsintheEAM-MTXgroupwere
still higher than those in the control group.
3.3. Changes in Echocardiographic Parameters. Echocardio-
graphic studies were performed to determine if MTX treat-
ment facilitates the improvement of cardiac structure and
function in postmyocarditis rats. Prior to MTX treatment,
the parameters of left ventricular remodeling including
LVEDD, LVESD, and LVMI in the EAM30 group were
higher than the control group (5.43 ± 0.21mm versus
5.26 ± 0.25mm, 2.38 ± 0.39mm versus 2.07 ± 0.32mm,
1.64 ± 0.14mg/g versus 1.24 ± 0.12mg/g, resp.). The
cardiac function in the EAM30 group was signiﬁcantly
decreased characterized by reduced FS (46.36% ± 5.69%
versus 60.77% ± 5.64%) and LVEF values (68.46% ± 8.13%
versus 86.62% ± 5.40%), compared with the control group.
Therewasnostatisticaldiﬀerencewhencomparinganyother
parameters between the two groups (Table 1). These results
suggest that there were signiﬁcant left ventricular dilation as
well as reduced cardiac contractility in postmyocarditis rats.
As shown in Table 2, the EAM60 group has higher
LVEDD, LVESD, and RWT and lower LVPWT and IVST than
the control group. Moreover, the LVEF, FS, and SV were also
all signiﬁcantly decreased in the EAM60 group compared
withthecontrolgroup,indicating aprogressivedevelopment
of left ventricular remodeling and cardiac dysfunction. In
contrast, these were signiﬁcant decreases of the LVEDD and
LVESD and increases of FS, LVEF, and SV in the EAM-4 Mediators of Inﬂammation
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Figure 1 :C h a n g e so fp l a s m ac y t o k i n e sl e v e l s .T h el e v e l so fT N F -
alpha, IL-6, and IL-10 were determined by ELISA. All results are
expressed as mean ± SD (n = 10).
∗P <. 01 versus control group;
#P <. 01 versus EAM60 group;

P<. 01 versus EAM30 group.
MTX group compared to the EAM60 group. The LVMI
remained similar among all three groups. These results
suggested that MTX treatment was beneﬁcial to reverse the
left ventricular dilation and increase cardiac systolic function
in postmyocarditis rats.
3.4. Histological Study. Hearts from the EAM60 group
showed macroscopic changes, included severe and diﬀuse
discoloration of the surface tissue. However, the size of
the discolored area was signiﬁcantly reduced in the EAM-
MTX group. Additionally, the EAM60 group rats exhibited
an enlarged ventricular chamber and thinned wall, as seen
in patients with DCM. In contrast, the enlargement of
Table 1: Echocardiographic baseline data of control and EAM rats
on day 30.
Group Control (n = 10) EAM30 (n = 20)
LVEDD (mm) 5.26 ± 0.25 5.43 ±0.21
∗
LVESD (mm) 2.07 ± 0.32 2.38 ±0.39
∗
LVPWT (mm) 1.62 ± 0.12 1.55 ±0.21
IVST (mm) 1.70 ± 0.22 1.58 ±0.20
LVMI (mg/g) 1.24 ± 0.12 1.64 ±0.14
∗
RWT 1.77 ± 0.22 1.80 ±0.29
FS (%) 60.77 ±5.64 46.36 ±5.69
∗
LVEF (%) 86.62 ±5.40 68.48 ±8.13
∗
SV (μL) 125.64 ±10.24 132.68 ±10.69
∗P <. 05 versus control group.
the ventricular chamber was signiﬁcantly attenuated in the
EAM-MTX group (Figure 2(a)). Microscopically, myocar-
dial degeneration, necrotic and alignment disorder of the
myocardial ﬁbers, observed in the EAM60 group rats.
Interestingly, the extent and area of lesions were dramatically
alleviated in the EAM-MTX group (Figures 2(b), 2(c),a n d
2(d)).
3.5. Myocardial Fibrosis. Masson’s trichrome staining
allowed the visualization of any myocardial interstitial
ﬁbrosis. As shown in Figure 3(a), only few green staining
collagen ﬁbroses were scattered between the red staining
myocytes and surrounding the blood vessels in the control
group. In contrast, the EAM60 group rats exhibited
more extensive and signiﬁcant green staining of collagen
ﬁbers (Figure 3(b)). To quantitatively compare the extent
of cardiac ﬁbrosis, CVF and PVCA, were respectively,
calculated in this study. The results showed that the EAM60
group rat had higher CVF and PVCA value than the control
group (Figures 3(d) and 3(e)), suggesting the occurrence
of signiﬁcant cardiac ﬁbrosis in postmyocarditis. However,
in the EAM-MTX group, the green staining of the collagen
ﬁbers was markedly reduced, compared with that in the
EAM60 group (Figures 3(b) and 3(c)). Quantitative analysis
showed that the CVF and PVCA in the EAM-MTX group
were signiﬁcantly lower than those in the EAM60 group
(Figures 3(d) and 3(e)).
The myocardial collagen matrix, consisting mainly of
collagen type I and III, is considered to be an important
determinant of myocardial structural integrity and cardiac
function. Excessive collagen deposition is essential to the
development of cardiac ﬁbrosis. To further identify which
kind ofcollagendeposition mainlyoccurredpostmyocarditis
and the role of MTX treatment on them, the collagen
type I and III were respectively stained. As a result, the
EAM60 group rats showed signiﬁcantly increased expression
of collagen type I and III, mainly type I, in myocardial
interstitium, compared with the control group. In the EAM-
MTX group, MTX treatment dramatically attenuated the
deposition of both collagen types I and III (Figure 4(a)).
Quantitative analysis also clearly demonstrated an markedly
increaseinthesizeoftheareastainingforcollagen,especiallyMediators of Inﬂammation 5
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Figure 2: Macroscopic and microscopic assessment of the hearts. (a) Representative gross appearance of the heart from each group of
rats. (b) Representative photomicrographs of the ventricular sections (HE staining; ×200). In hearts from the control group, myocytes is
well organized. In EAM60 group, the cardiac myocytes exhibited extensive necrosis, degeneration, and disorder. MTX treatment led to a
signiﬁcant decrease in the size of these lesions.
Table 2: Comparison of echocardiograph parameters of all three groups rats on day 60 (n = 10).
Groups Control EAM60 EAM-MTX
LVEDD (mm) 5.69 ± 0.29 6.46 ±0.28
∗ 6.06 ±0.37

LVESD (mm) 2.24 ± 0.30 4.20 ±0.67# 2.74 ± 0.41∗,
LVPWT (mm) 1.74 ± 0.17 1.54 ±0.20
∗ 1.65 ± 0.21
IVST (mm) 1.76 ± 0.17 1.56 ±0.19
∗ 1.68 ± 0.20
LVMI (mg/g) 1.52 ± 0.04 1.62 ± 0.17 1.60 ± 0.14
RWT 1.73 ± 0.24 2.12 ±0.32
∗ 1.86 ± 0.35
FS (%) 62.31 ± 6.86 35.27 ±8.02# 55.02 ± 4.16∗,
LVEF (%) 89.87 ± 4.40 62.73 ±10.11# 84.77 ± 3.60
SV (μL) 162.38 ± 25.39 132.36 ±11.30
∗ 156.02 ± 15.29

∗P <. 05, #P<. 01 versus control group;

P < .05, P < .01 versus EAM60 group.
f o rt y p eI ,a sw e l la sa ni n c r e a s e dc o l l a g e nt y p eI / I I Ir a t i oi n
the EAM60 group compared to the control group. Notably,
boththestainingareasofcollagenI/IIIandcollagentypeI/III
ratio were signiﬁcantly decreased in the EAM-MTX group
compared to the EAM60 group, but still greater than those
of the control group (Figures 4(b) and 4(c)).
4. Discussion
In the present study, we observed that the proinﬂammatory
cytokines, including TNF-alpha and IL-6, were signiﬁcantly
increased in postmyocarditis rats. However, we demon-
strated, for the ﬁrst time, that MTX administration not only
enables to reduce the level of proinﬂammatory cytokine
and increase the level of anti-inﬂammatory cytokine but
also simultaneously attenuates the ventricular dilation and
myocardial ﬁbrosis as well as enhances cardiac function.
The EAM model has been extensively characterized in
rats and is initiated by immunization with cardiac myosin
which, among other eﬀects, provokes a strong inﬂamma-
tory response. In the recovery phase of the inﬂammation,
immunized animals will progress to DCM [18]. Several
studies have demonstrated that early administration of
anti-inﬂammatory therapies can eﬀectively attenuate the6 Mediators of Inﬂammation
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Figure 3: Masson’s trichrome staining. Representative photomicrographs of the ventricular sections from the three groups of rats are shown
(×200). Green staining represents the collagen ﬁbers (a)–(c). Myocardial collagen volume fraction (CVF; (d)) and perivascular collagen area
(PVCA; (e)) were calculated in the control, EAM60 and EAM-MTX groups, respectively. All results are represented as mean ± SD (n = 10).
∗P <. 05, #P <. 01 versus control group; P <. 01 versus EAM60 group.
induction of EAM [19, 20]. However, it remains unclear
whether later anti-inﬂammatory treatment could further
prevent the progression of cardiac remodeling in the stage of
postmyocarditis. Therefore, in this study, we used the cardiac
myosin-inducedratEAMmodeltoexploretheeﬀectofMTX
on the development of DCM in postmyocarditis rats.
We recently demonstrated that MTX has signiﬁcant anti-
inﬂammatory eﬀects for patients with CHF resulting from
various causes. Following MTX treatment, these patients
showed an improvement in their clinical status [21]. How-
ever, MTX treatment failed to improve LVEF and reduce
LVEDD in patients with CHF. CHF subjects display a large
heterogeneity in the degree of immune and inﬂammatory
activation [2]. Given this, we hypothesized that MTX treat-
ment would be suitable for the treatment of CHF patients,
especiallyfortheseduetotheinﬂammatorycardiomyopathy.
In this study, we showed that MTX treatment not only
resulted in signiﬁcantly decreased plasma levels of TNF-
alpha and IL-6 in postmyocarditis rats but more importantly
increased the expression of IL-10. Since IL-10, as a potent
anti-inﬂammatorycytokine,isastrongdeactivatorofmono-
cyte and suppressor of various proinﬂammatory mediators
[9, 10], these results suggest that MTX treatment can obtain
a favorable anti-inﬂammatory net eﬀect. However, it is
important to note that we previously failed to observe these
eﬀects of MTX in healthy rats (unpublished data). It has
been shown that the excessive activation of proinﬂammatory
cytokines TNF-alpha can mimic a number of aspects of
the CHF phenotype, including left ventricle remodeling. It
is reasonable to propose, then, that the anti-inﬂammatory
eﬀects of MTX may result in improved cardiac remodeling
and function in postmyocarditis rats.
Types I and III collagens are major structural proteins
forming the myocardial collagen matrix. Excessive collagen
deposition in myocardium will lead to cardiac ﬁbrosis. Since
Type I collagen determines the stiﬀness of the myocardium,
while type III collagen contributes to its elasticity, the altered
collagen I/III ratio has critical impact on the diastolic and
systolic function of the heart [22] .I nt h i ss t u d y ,w eo b s e r v e d
that MTX treatment not only signiﬁcantly reduced the
deposition of collagens but also decreased the collagen type
I/III ratio, suggesting a beneﬁcial role of antiﬁbrosis and
cardiac function. Meanwhile, we have clearly demonstrated
that MTX treatment also markedly relieved ventricular
dilation and enhanced cardiac systolic function. Collectively,
the above results suggested that low-dose MTX treatment
enables to elicit beneﬁcial eﬀects in cardiac remodeling and
function in postmyocarditis, maybe through restoring theMediators of Inﬂammation 7
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Figure 4: Collagen types I and III staining. Representative photomicrographs of ventricular sections from the three groups of rats are shown
((a); ×200). The areas of collagen types I and III were, measured (b) and the ratios of collagen type I/III were calculated (c). All results are
represented as mean ± SD (n = 10).
∗P < .05, #P < .01 versus control group;
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balance between proinﬂammatory and anti-inﬂammatory
cytokines. Therefore, in certain extent, it will facilitate to
prevent the development of postmyocarditis DCM. Consis-
tent with this study, atorvastatin, an HMG-CoA reductase
inhibitor, has recently been shown to regulate the Th1/Th2
cytokine imbalance and to attenuate the histopathological
severity of myocarditis [23]. Moreover, in acute myocardial
infarction rats, persistent myocardial inﬂammatory response
has adverse eﬀects on LV function and remodeling. However,
administration of recombinant IL-10 recently has been
shown to signiﬁcantly suppress inﬁltration of inﬂammatory
cells and expression of proinﬂammatory cytokines in the
myocardium as well as improve LV function and remodeling
by inhibiting cardiac ﬁbrosis [24].
However, the anti-inﬂammatory mechanism of MTX in
EAM rats remains elusive. Previous studies showed that
MTX exerts its anti-inﬂammatory eﬀect by inducing T
cell apoptosis, inhibiting neutrophil and mononuclear cells
inﬁltration [17, 25]. However, an in vitro study demon-
strated that the anti-inﬂammatory eﬀect of low-dose MTX
is, at least partly, due to regulation of T cell activation and
adhesion molecule expression [26]. In addition, in patients
with rheumatoid arthritis, MTX treatment has been shown
t or e d u c ei n ﬂ a m m a t o r yc e l ln u m b e r sa sw e l la sl e v e l so f
monokines and adhesion molecules in the synovial tissue
[13].
There are some limitations in this study. Circulating
immune cells are the main source of plasma cytokines.
To date, the primary source of activated inﬂammatory
mediators involved in CHF remains elusive. Previous studies
indicated that autoreactive CD4+ T cells and mononuclear
cells have a role in the myocardial inﬂammatory inﬁltration
and the production of cytokines in EAM rats; however,
the role of MTX on the function of circulating T cells
and mononuclear cells still requires further investigation.
Additionally, the regulatory role of MTX on the local,
myocardial expression of inﬂammatory mediators is unclear.
In summary, low-dose MTX treatment facilitates to
attenuate the inﬂammatory response and improve cardiac
remodeling and function in postmyocarditis rats.
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